HOME >> BIOLOGY >> NEWS
Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax

within a few days, some spores can remain dormant for much longer periods, which poses special challenges with regard to postexposure treatment. According to Friedlander, antibiotics are active only after spores have germinated; therefore, dormant spores that germinate after therapy has been discontinued can cause disease and death. This delayed germination necessitates prolonged use of antibiotics after an inhalational exposure.

Animal experiments have confirmed the prolonged persistence of spores and incubation period after aerosol exposure. In one study, rhesus macaques were protected during a 30-day course of antibiotics after aerosol exposure. However, some animals developed fatal infection after the antibiotic therapy was discontinued.

"In spite of the low compliance rates we saw in 2001--where more than half of the people did not take the full 60-day course--there were no additional anthrax cases," Friedlander commented. "This suggests that the doses of inhaled spores were probably very low. In contrast, computer modeling suggests that protection against higher doses of anthrax spores could require that antibiotics be continued for as long as four months. Adding vaccine to a postexposure regimen of antibiotics may shorten the duration and thus avoid the problems of noncompliance associated with a prolonged course."

Colonel George W. Korch, Jr., USAMRIID commander, added, "The tremendous value of interagency collaboration cannot be understated in this very important finding, which stands to potentially improve the course of therapeutic intervention, as well as enhance overall protection against this significant biological threat."


'"/>

Contact: Caree Vander Linden
Caree.Vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
1-May-2006


Page: 1 2 3

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine hope for sufferers of potentially fatal stomach bug
5. Vaccine to cope with viral diversity in HIV
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
8. Vaccine-producing plant-factories
9. HPV Vaccine: Whats next
10. Vaccine shown effective against chancroid
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
(Date:10/17/2014)... Why do male ... reproduce? And why are there two sexes anyway? These and ... the research journal Molecular Human Reproduction published today ... University Bielefeld has compiled this special issue on sperm competition. ... copulate with several males in quick succession – chimpanzees are ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2
(Date:10/25/2014)... 2014 Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, announced ... will present at FireRock Capital,s Micro-Cap Conference. ... ,Date: Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: ... City , About The FireRock ...
(Date:10/25/2014)... October 24, 2014 Investor-Edge has ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ... these five companies can be accessed at: http://investor-edge.com/register ... 23, 2014, ended on a positive note as the ...
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines ... with analysis and forecast of revenue. , Browse ... Market report, to get an idea of the ... of the segmentation in the Americas inorganic refrigerants ... figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
Cached News: